Merck and Moderna Announce 42 Percent Drop in Melanoma Risk

A new cancer treatment has just cleared a major hurdle in clinical testing.

Pharmaceutical partners Merck and Moderna announced on Thursday that a personalized mRNA vaccine reduced the risk of death or recurrence by 42 percent in patients with melanoma. This specific form of skin cancer is considered the deadliest variety. The figures come from a late-stage trial that compared the new vaccine against standard care protocols.

The trial involved 1,137 patients who had stage IIB to IV melanoma. All participants had already undergone surgery to remove their tumors before entering the study. Researchers randomized the patients into two groups at a ratio of two to one. One group received the personalized mRNA vaccine alongside standard treatment. The other group received only the standard treatment, which consisted of Merck’s monoclonal antibody drug Keytruda.

The announcement follows a successful report in August when the companies first noted the vaccine’s efficacy. At that time, they withheld specific details until the data could be presented at a scientific conference. That event is the European Society of Medical Oncology meeting currently underway in Madrid, Spain. The data was originally scheduled for a Saturday presentation. However, an oncology news site reported the results early and broke the embargo. This prompted the companies to release the top-line figures immediately. The full dataset has been accepted for publication in the New England Journal of Medicine.

Stéphane Bancel, the chief executive officer of Moderna, commented on the results in a written statement. He noted that the company has believed since the beginning that mRNA technology could allow for cancer treatments uniquely matched to each patient’s tumor. Bancel described the trial outcomes as a defining moment for that vision. He added that the results show what is possible when the industry rethinks how medicines are made.

Bancel also stated that the findings reinforce the company’s conviction. He believes mRNA has the potential to fundamentally change how cancer is treated. The success of this specific vaccine bolsters hope for a broader shift in oncology. It suggests that individualized cancer-targeting medicines may represent a new paradigm for therapies.

The results mark a significant advance in the treatment of melanoma. Given the magnitude of the data, Merck and Moderna are already engaging with regulatory authorities. Their goal is to secure approval for the vaccine. This move signals a fast-track approach to bringing the therapy to market.

The stakes are high for patients and providers alike. A 42 percent reduction in risk is a substantial improvement over current standards of care. As the companies push for regulatory sign-off, the focus turns to how quickly this personalized approach can become widely available. The data from Madrid will continue to shape the conversation in the oncology community this week.